+ T cells in pulmonary fibrosis, supporting the use of readily available therapeutics that directly address interstitial lung disease pathophysiology.
INTRODUCTION
Pulmonary fibrosis represents progressive remodeling of lung ar chitecture by deposition of connective tissue elements after persistent stimulation from antigenic (for example, Schistosoma eggs) and non antigenic sources (for example, bleomycin in a mouse model) (1) (2) (3) . Although tissue repair in its early stages is beneficial, continued con nective tissue deposition results in scarring that eventually leads to organ fibrosis and death without therapeutic interventions (4) . While new therapies continue to emerge, enhancing our understanding of the immunologic foundation responsible for pulmonary fibrosis re veals innovative therapeutics that directly target pathophysiology. Numerous cytokines have been implicated in pulmonary fibrosis (5) (6) (7) . The importance of interleukin17A (IL17A)-producing CD4 + T cells has been demonstrated in pulmonary fibrosis (8) . Increased IL17A in the bronchoalveolar lavage of idiopathic pulmonary fibro sis (IPF) patients has also been reported (9) . Longitudinal increases in programmed cell death1 (PD1) + CD4 + T cells are present during sarcoidosis pulmonary progression, with T helper 17 (T H 17) cells as the T cell subset expressing the greatest percentage of PD1 (10) . Furthermore, genomewide association studies implicate the T H 17 signaling pathway in sarcoidosis pulmonary progression (11) ; tran scriptomic analysis implicates adaptive immune dysfunction in IPF (12, 13) .
To date, a link establishing PD1 and IL17A interactions in pul monary fibrosis has not been established. The purpose of the cur rent study is to use two disease systems, IPF and sarcoidosis, to test the hypothesis that PD1 upregulation on T H 17 cells induces pul monary fibrosis. Here, we report that PD1 + CD4
+ T cells produce both transforming growth factor- (TGF) and IL17A through increased signal transducer and activator of transcription 3 (STAT3) transcription. Coculture of CD4 + T cells with human lung fibro blasts (HLFs) induces collagen1 production; while blockade of the PD1 pathway significantly decreases both STAT3, TGF and IL17A expression, with concurrent reductions in collagen1. These findings establish the biological significance of the PD1 pathway, suggest ing STAT3, IL17A, or PD1 as potential therapeutic targets for pa tients suffering from pulmonary fibrosis.
RESULTS

PD-1 +
CD4
+ T cells with diminished proliferative capacity are present in IPF subjects To delineate the role of coinhibitory molecules in interstitial lung disease, we first examined PD1 expression on systemic IPF CD4 + T cells. PD1 cell surface expression was significantly higher on IPF CD4 + T cells compared to healthy controls (HC) (P < 0.0001, un paired twotailed t test) ( Fig. 1A ; gating strategy is shown in fig. S1A ). Increased PD1 expression on IPF CD4 + T cells was still apparent after restricting analysis to agematched HC subjects (P = 0.02, un paired twotailed t test; fig. S1B and Table 1 ). We then defined the IPF CD4 + T cell subset demonstrating the highest percentages of PD1 + T cells. Intriguingly, PD1
+ T H 17 cells were the highest [P < 0.001, oneway analysis of variance (ANOVA) with Tukey's post hoc test], as was seen in sarcoidosis subjects ( Fig. 1B and fig. S1C ). The functional significance of PD1 upregulation was demonstrated by significant reductions in proliferative capacity in IPF PD1 + CD4 + T cell CD3/CD28 T cell receptor (TCR) stimulation (P < 0.0001, un paired twotailed t test; Fig. 1C ).
To examine whether PD1 pathway expression is also present in IPF lungs, immunohistochemical analysis for PD1 expression in IPF human lung biopsies was performed. Increased PD1 expres sion was detected in 10 IPF lungs compared to 5 HC lungs. Repre sentative sections are shown in Fig. 1D . PDL1 expression was also noted within IPF biopsies (Fig. 1D) . Grading the prevalence of PD1 in IPF and HC samples revealed that IPF specimens had significantly higher PD1 + lymphocytes than HC specimens (Fig. 1E ).
PD-1 + T H 17 cells display the highest expression of TGF-1
TGF is synthesized and processed within the cell and then secreted as a large latent TGF complex in which it is bound to latency associated peptide (LAP) (14) . Excessive TGF production results in organ fibrosis and, eventually, compromised organ function (15, 16) . The presence of PD1 + CD4 + T cells in fibrosing condi tions, such as IPF and sarcoidosis, led us to examine whether CD4 + T cells from these subjects secrete TGF and whether distinctions in TGF expression by T cell subsets are present. Active TGF1 expression was in ~70% of sarcoidosis and IPF CD4 + T cell cul tures compared to ~30% in HC (HC/sarc, P = 0.03; HC/IPF, P = 0.01; oneway ANOVA with Tukey's post hoc test). No significant differences were observed in active TGF1 between sarcoidosis and IPF CD4 + T cells ( Fig. 2A) . A greater percentage of total CD4 + T cells producing membranebound TGF1 (LAP/TGF1) in sar coidosis and IPF patients compared to HC was also (P < 0.0001, oneway ANOVA with Tukey's post hoc test). LAP/TGF1 mean fluorescence intensity (MFI) was also significantly increased in sarcoidosis and IPF CD4 + T cells compared to HC (P < 0.01, one way ANOVA with Tukey's post hoc test; Fig. 2B ) (representative histograms are shown in fig. S2 , A to C). PD1 upregulation was seen on sarcoidosis and IPF CD4 + T cells expressing TGF1 (Fig. 2C ). These findings demonstrate the presence of TGF-secreting CD4 + T cells with PD1 upregulation in patients with fibrotic lung disease.
TGF promotes the development of regulatory T cells (T regs ) through the transcription factor FOXP3 (17) . Hence, we investigated whether increased TGF1 expression observed in CD4 + T cells was derived from T regs . We first examined the overall percentages of T regs in sarcoidosis and IPF patients. The percentage of T regs was higher in sarcoidosis subjects only compared to HC (HC/sarc, P < 0.001; HC/IPF, P = 0.08, oneway ANOVA with Tukey's post hoc test; fig. S3A ). No significant differences in LAP/TGF1 produc tion by sarcoidosis or IPF T regs were apparent (HC/sarc, P = 0.45; HC/IPF, P = 0.38; P = 0.08, oneway ANOVA with Tukey's post hoc test; Fig. 2D ). No distinctions in PD1 expression on sarcoidosis or IPF T regs producing TGF1 were seen (P = 0.30, oneway ANOVA with Tukey's post hoc test; Fig. 2E ) (representative histogram is shown in fig. S3B ).
The proinflammatory cytokine IL6 modulates TGF promo tion of induced T reg development in favor of T H 17 development (18) (19) (20) . We detected increased IL6 production in systemic sar coidosis CD4 + T cells compared to HC CD4 + T cells (P < 0.0001, unpaired twotailed t test; fig. S4 ). We therefore examined LAP/ TGF1 secretion from T H 17 cells. A significant difference in LAP/ TGF1 secreted by sarcoidosis and IPF T H 17 cells compared to HC was noted (HC/sarc, P = 0.03; HC/IPF, P = 0.0092, oneway ANOVA with Tukey's post hoc test; Fig. 2F ). The sarcoidosis T H 17 cells that demonstrated increased frequency and intensity of LAP/TGF1 were derived from patients with high baseline PD1 MFI (P = 0.04, oneway ANOVA with Tukey's post hoc test) but not those with baseline PD1 MFI consistent with HC (P = 0.9534; high/low, P = 0.03; oneway ANOVA with Tukey's post hoc test; Fig. 2F ). We ob served significantly higher PD1 on sarcoidosis and IPF T H 17 cells expressing TGF1compared to HC (P < 0.0001, oneway ANOVA with Tukey's post hoc test; Fig. 2G ). T H 1 cells, not producing IL17A, from sarcoidosis and IPF patients produced higher amounts of LAP/TGF1 compared to HC (HC/sarc, P = 0.02; HC/IPF, P < 0.01; oneway ANOVA with Tukey's post hoc test; fig. S5A ). IPF CD4 + T cells that were dual producers of IL17A and interferon (IFN) had significantly higher LAP/TGF1 expression compared to HC (P < 0.001), but LAP/TGF1 expression by sarcoidosis subjects was not distinct (P = 0.68, oneway ANOVA with Tukey's post hoc test; fig. S5B ). The percentage of T follicular helper cells producing LAP/ TGF1 was higher in IPF patients (P < 0.01, oneway ANOVA with Tukey's post hoc test), but not in sarcoidosis subjects (P = 0.89, one way ANOVA with Tukey's post hoc test; fig. S5C ). Evaluation of TGF1 expression by PD1 in CD4 + T cells showed significantly more TGF1 production by PD1-positive cells then PD1-negative cells (sarc, P < 0.0001; IPF, P = 0.03; unpaired twotailed t test; fig.  S5D ). Collectively, T H 17 cells had the highest percentage of TGF1 secretion in sarcoidosis and IPF cohorts (Fig. 2H) . Assessment of intracellular TGF1 expression by flow cytometry revealed sig nificantly higher expression in sarcoidosis and IPF CD4 + T cells producing IL17A compared to HC (P = 0.02 and P = 0.0032, re spectively, unpaired twotailed t test; fig. S6 , A to C).
PD-1 pathway blockade reverses the capacity of sarcoidosis and IPF CD4
+ T cells to induce HLF-derived collagen-1 production in vitro To determine the biological and physiological significance of increased TGF1 secretion by sarcoidosis and IPF T H 17 cells, we assessed collagen1 production after coculture of HLF with patient CD4 + T cells. We isolated HC, sarcoidosis, and IPF CD4 + T cells to 90 to 98% 3 of 14 purity and cocultured each with an HLF cell line. Figure S7A depicts the gating strategy using flow cytometry. During analysis, we gated out CD3 + CD4 + T cells and used the absence of CD45 expression to iden tify the fibroblast population as established previously (21, 22) .
We observed a significant increase in percentage of collagen1 produced by fibroblasts cocultured with sarcoidosis or IPF CD4 + T cells compared to HLF cultured alone or in combination with HC CD4 + T cells (HC and HLF, P = 0.76; sarcoidosis and HLF, P < 0.0001; IPF and HLF, P < 0.01; overall, P = 0.01, oneway ANOVA with Tukey's post hoc test; Fig. 3, A and B) . Elevated collagen1 was also observed in coculture supernatants by enzymelinked immunosorbent assay (ELISA), confirming the aforementioned results (sarcoidosis, P = 0.0031; IPF, P < 0.0001, overall oneway ANOVA with Tukey's post hoc test; Fig. 3, A and B) . We repeated the coculture experiments with four other distinct HLF lines and noted increased collagen pro duction in those as well (table S1) . Notably, only sarcoidosis CD4 + T cells with high PD1 induced collagen1 production, whereas CD4 + T cells with PD1 expression akin to HC did not induce collagen1 production after coculture experiments with HLF (P = 0.14, oneway ANOVA; fig. S7 , B and C).
Increased collagen1 production after coculture of TCRstimulated PD1 + CD4 + T cells with HLF led us to examine the effects of PD1 pathway blockade on HLFderived collagen1 production. Purified sarcoidosis CD4 + T cells were cultured overnight with or without the addition of PD1, PDL1, and PDL2 blocking anti bodies, followed by CD3/CD28 TCR stimulation. HLFs were added the fol lowing day at a 1:10 ratio (HLF/T cell). The percentage of collagen1 Comparisons between cohorts were performed using an unpaired two-tailed Student's t test. Multiple group comparisons were performed using a one-way ANOVA with Tukey's post hoc test. Proliferation data were analyzed using the Mann-Whitney U test. Bars indicate SEM. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. NS, no significance; CFSE, carboxyfluorescein diacetate succinimidyl ester; FMO, fluorescence minus one. Comparisons between cohorts were performed using an unpaired two-tailed Student's t test. Multiple group comparisons were performed using a one-way ANOVA with Tukey's post hoc test. Bars indicate SEM. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. NS, no significance for (A) to (G).
produced by HLF (CD3 − CD4 − CD45 − ) cultured in the presence of sarcoidosis CD4 + T cells after PD1 pathway blockade dropped from 13.5% (mean) preblockade to 7.5% (mean) postblockade analogous to the control group [HLF alone (mean, 7.5%)]. This decline reflects a 44% reduction in collagen1 production from HLF (Fig. 3C ). Fibro blast collagen1 expression was only reduced in the cells that had been cultured with sarcoidosis CD4 + T cells expressing high baseline PD1 (P < 0.001, paired twotailed t test; Fig. 3C ), but not in those that had been cultured with sarcoidosis T cells from patients who expressed PD1 levels akin to HC (P = 0.25, paired two tailed t test; Comparisons between cohorts were performed using an unpaired two-tailed Student's t test. Preblockade and PD-1 pathway blockade cohort comparisons were analyzed using a paired Student's t test. Multiple group comparisons were performed using a one-way ANOVA with Tukey's post hoc test. Bars indicate SEM. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. NS, no significance; GAPDH, glyceraldehyde-3-phosphate dehydrogenase. fig. S7D ). Reductions in collagen1 production from HLF after PD1 pathway blockade of IPF CD4 + T cells were also apparent (P < 0.01, oneway ANOVA with Tukey's post hoc test; Fig. 3D ) (representative histograms are shown in fig. S7E ). We conducted confirmatory ELISA for collagen1 production in coculture supernatants after 24 hours of HLF cocul ture with TCRstimulated sarcoidosis PD1 + CD4
+ T cells and noted a significant increase in collagen production between baseline (HLF only) and preblockade conditions (P = 0.03, paired twotailed t test), as well as a significant reduction in collagen after PD1 pathway block ade (P = 0.03, paired twotailed t test; Fig. 3E ). These results were con firmed by Western blot using antibodies against COL1A1, -smooth muscle actin (SMA), and fibronectin (Fig. 3F ). Significant differences in COL1A and SMA expression were noted (P = 0.01 and P < 0.001, respectively; overall, oneway ANOVA with Tukey's post hoc test); reduced fibronectin expression was also noted (P = 0.07; overall, one way ANOVA with Tukey's post hoc test; Fig. 3F ). No significant differences were noted in the culture supernatant by Western blot assays ( fig. S8 ). These results indicate that PD1 + CD4 + T cells have the capacity to induce pulmonary fibrosis through stimulation of HLF collagen1 production.
PD-1 regulates IL-17A and TGF-1 expression in sarcoidosis and IPF CD4
+ T cells To understand how PD1 regulates collagen1 production by HLF, we assessed for two key mediators of organ fibrosis: IL17A and TGF1. After PD1 pathway blockade, the percentage of sarcoid osis IL17A-producing CD4 + T cells in the coculture experiments . Comparisons between cohorts were performed using an unpaired two-tailed Student's t test. Preblockade and PD-1 pathway blockade cohort comparisons were analyzed using a paired Student's t test. Multiple group comparisons were performed using a one-way ANOVA with Tukey's post hoc test. Bars indicate SEM. *P < 0.05, **P < 0.01. NS, no significance.
7 of 14 Comparisons between cohorts were performed using an unpaired two-tailed Student's t test. Preblockade and PD-1 pathway blockade cohort comparisons were analyzed using a paired Student's t test. Multiple group comparisons were performed using a one-way ANOVA with Tukey's post hoc test. Bars indicate SEM. *P < 0.05, **P < 0.01. NS, no significance.
significantly declined from a mean of 15% to a mean of 3%, reflect ing an 80% reduction (P < 0.01, paired twotailed t test; Fig. 4A ).
The detection of PD1 + T H 17 cells in sarcoidosis and IPF subjects supported further inquiry into the effects of PD1 pathway block ade on TGF1, a key mediator of T H 17 development. PD1 path way blockade significantly reduced TGF1 secretion in sarcoidosis and IPF CD4 + T cells (P < 0.01 and P = 0.04, respectively; paired twotailed t test; Fig. 4, B and C) . Representative histograms are depicted in fig. S9 (A to C) . Using ELISA analysis, we confirmed increased active TGF1 expression after HLF coculture with sar coidosis CD4 + T cells, accompanied by significantly reduced expres sion after PD1 pathway blockade (P = 0.01, oneway ANOVA with Tukey's post hoc test; Fig. 4D ). To confirm the source of TGF1 in coculture experiments, we assessed for TGF1 expression by T H 17 cells using flow cytometry. PD1 pathway blockade effectively re duced TGF1 secretion from T H 17 cells in sarcoidosis subjects with high baseline PD1 (P = 0.04, paired twotailed t test; Fig. 4E ), but not in subjects with PD1 levels akin to HC (P = 0.49, paired two tailed t test; Fig. 4F ). TGF1 expression was significantly reduced in IPF T H 17 cells after blockade of PD1 pathway (P = 0.02, paired twotailed t test; Fig. 4G ).
PD-1 blockade reduces expression of the transcription factors STAT3 and RORC in CD4
+ T cells STAT3 is an essential transcription factor for T H 17 cell development (23) . To identify the molecular mechanism by which PD1 regulates IL17A production, we first focused on STAT3 expression. Flow cyto metric analysis revealed significantly higher STAT3 expression in sarcoidosis subjects compared to HC after CD3/CD28 TCR stimu lation (percentage, P = 0.03; MFI, P = 0.01, unpaired twotailed t test; Fig. 5A ). We also conducted quantitative PCR analysis for STAT3 mRNA expression in HC, sarcoidosis, and IPF CD4 + T cells. A significant increase in STAT3 mRNA expression in sarcoidosis and IPF subjects was apparent compared to HC (HC/sarc, P = 0.01; HC/IPF, P = 0.01; P < 0.01, oneway ANOVA with Tukey's post hoc test) (Fig. 5B ). Significant differences between sarcoidosis and IPF subjects were not detected (P = 0.14, oneway ANOVA with Tukey's post hoc test; Fig. 5B ). We then assessed STAT3 mRNA expression after PD1 pathway blockade in sarcoidosis CD4 + T cells. Significant reductions in STAT3 mRNA expression were detected after PD1 blockade (P = 0.04, paired twotailed t test; Fig. 5C ). To confirm that the PD1 pathway regulates collagen1 production through phosphoSTAT3 (pSTAT3)-mediated IL17A production, we used the smallmolecule inhibitor of pSTAT3, STATTIC (24) . After STATTIC administration to sarcoidosis CD4 + T cells overnight, co culturing of these cells with HLF resulted in significant reductions in collagen1 production (P = 0.0032, oneway ANOVA with Tukey's post hoc test) to baseline levels (that is, HLF cultured alone) (P = 0.82, oneway ANOVA with Tukey's post hoc test; Fig. 5D ). Significant reductions in IL17A-producing CD4 + T cells after STATTIC inhi bition were also noted (P = 0.0032, paired twotailed t test; Fig. 5E ), thus underlying the physiologic significance of STAT3mediated T H 17 cell differentiation in pulmonary fibrosis. Although diminution of IL17A expression is one mechanism relevant to STATTIC inhibition of collagen production, the capacity for STATTIC to inhibit STAT1 in T cells may also have a role (fig. S10 ).
Because our results demonstrated that both these factors are in creased in sarcoidosis patients, we examined RARrelated orphan receptor C (RORC) expression in CD4 + T cells. A significant increase in RORC mRNA was apparent between HC and sarcoidosis patients (P = 0.02, oneway ANOVA with Tukey's post hoc test; fig. S11A ). RORC expression was significantly reduced after PD1 blockade (P = 0.03, oneway ANOVA with Tukey's post hoc test) to control levels (P = 0.97, oneway ANOVA with Tukey's post hoc test; fig. S11A ).
Comparison of T regs and T H 17 cells from sarcoidosis and IPF patients based on PD1 expression demonstrated an imbalance in the ratios of these PD1 + subsets that was not apparent in PD1-negative cells (P < 0.0001, oneway ANOVA with Tukey's post hoc test; fig. S11 , B and C). Furthermore, IL6 has also been reported to induce the conver sion of FOXP3 + T regs into T H 17 cells in autoimmune disorders (25, 26) . We therefore examined RORC expression using flow cytometry in PD1-positive and PD1-negative sarcoidosis and IPF T regs . Our results demonstrated a significant increase in RORC expression in PD1 + FOXP3
+ cells from both sarcoidosis and IPF patients compared to PD1-FOXP3 + cells (sarc, P < 0.0001; IPF, P = 0.0041; unpaired twotailed t test; fig. S11, D and E).
Elevated expression of T H 17-related pathway genes is associated with reduced IPF life expectancy
To further assess the relevancy of T H 17 cells in interstitial lung dis eases, we screened PBMCs from IPF patients for differences in gene expression profiles and clinical outcomes. Two distinct T H 17 gene profiles were evident with significant differences in transplantfree survival (TFS) in the discovery cohort [hazard ratio (HR), 2.77; 95% confidence interval (CI), 0.96 to 8.01; P = 0.042; Fig. 6A ]. Similar to the cellular investigation, enhanced TFS was present among IPF sub jects having genetic signatures of reduced TGF and IL17A and in creased IFN expression (Fig. 6A) . Similar results were observed in the validation cohort where two clusters of patients were found to have significant differences in overall survival (HR, 5.24; 95% CI, 2.09 to 13.08; P = 0.0001; Fig. 6B ). The HR for mortality and TFS ranged from 2.77 to 5.24, indicating an increased risk of dying or re quiring a lung transplant for survival in patients with a genetic pro file consistent with increased T H 17 cell signatures (Fig. 6, A and B) . High STAT3 expression was also found to be a predictor of worse TFS in IPF patients (P = 0.005), with an HR of 3.82 (Fig. 6C) . These results were confirmed in the validation cohort with an HR of 3.5 ( Fig. 6D) , which suggest that dysregulation of T H 17 genes is associated with IPF progression and poor disease outcome, providing further evidence of T H 17 cell involvement in human interstitial lung disease.
The cohort with better TFS also demonstrated increased STAT4 expression, which could be secondary to increased IL12 production. IL12 in combination with other cytokines, such as IL7, promotes the differentiation of IFN-producing CD4 + T cells. However, in vitro human studies have shown that increased IL12 can drive the expansion of IL17A-producing CD4 + T cells (27) . Microarray analy sis of the discovery cohort demonstrated that increased IL12A and IL12B expression was associated with reduced TFS in IPF patients (P = 0.03 and P = 0.002, respectively; fig. S12 ).
Bleomycin murine model reveals reduced fibrosis in PD-1 null mice
To evaluate the presence of PD1 + CD4 + T cells in pulmonary fibro sis induced by other mechanisms, we assessed for their presence in murine lungs after intratranasal bleomycin administration, a model of pulmonary fibrosis due to acute lung injury. PD1 upregulation and diminished effector function were noted in CD4 + T cells from singlecell lung suspensions of bleomycintreated C57BL/6 mice (Fig. 7) . The percentage of unstimulated CD4 + T cells expressing PD1 and PD1 MFI was significantly higher at day 21 after treat ment in the bleomycintreated group than that in the phosphate buffered saline (PBS)-treated group (percentage, P = 0.02; MFI, P < 0.01; unpaired twotailed t test; Fig. 7A ). After TCR stimulation ex vivo, both groups demonstrated increased PD1 expression, with a signifi cantly higher percentage of CD4 + T cells expressing PD1 in the bleomycin treated group (P < 0.01, unpaired twotailed t test; Fig. 7B) . Notably, PD1 upregulation was accompanied by reduced CD4 + T cell pro liferation in the bleomycintreated mice compared to cells obtained from control mice (P < 0.001, unpaired twotailed t test; Fig. 7C ), thus confirming the functional significance of PD1 upregulation on pulmonary CD4 + T cells after bleomycin administration. T H 17 cells from singlecell lung suspensions of bleomycintreated mice also displayed increased LAP/TGF1 secretion in comparison to cells from PBStreated mice (Fig. 7D) . Furthermore, no signifi cant differences in TGF1 expression were apparent between T regs from the control and bleomycintreated mice (P = 0.92, unpaired twotailed t test; Fig. 7E ). When comparing TGF1 secretion from CD4 + T cells after bleomycin administration, we observed that T H 17 cells were responsible for most of the LAP/TGF production (P < 0.0001, oneway ANOVA with Tukey's post hoc test) among the CD4 + T cell subsets (Fig. 7F) . The detection of PD1 + CD4 + T cells in a model of pulmonary fibrosis due to acute lung injury indicates that PD1 pathway may be a common point of immunologic convergence in pulmonary fibrosis despite the etiology.
To determine whether interrupting the PD1 pathway can dampen fibrosis, wildtype (WT) and PD1 null C57BL/6 mice were chal lenged with bleomycin via intranasal administration and were then euthanized at day 14. In separate experiments, WT mice were either Fibrosis degree and severity were significantly higher by Ashcroft scoring in WT C57BL/6 compared to PD1 null mice (Fig. 7G) . Assessment of hydroxyproline content by HPLC confirmed these distinctions (Fig. 7G) . Significantly lower levels of hydroxyproline were noted in PD1 null mice compared to WT C57BL/6 (41.7 + 17.0 isotype and anti-PD-L1 antibody treatment (n = 10 and n = 12, respectively). (K) Linear correlation between PD-1 and pSTAT3 (Y705) after bleomycin administration. Comparisons between cohorts were performed using an unpaired two-tailed Student's t test. Preblockade and PD-1 pathway blockade cohort comparisons were analyzed using a paired Student's t test. Multiple group comparisons were performed using a one-way ANOVA with Tukey's post hoc test. Proliferation data were analyzed using the Mann-Whitney U test. PD-1/pSTAT3 correlation analyzed using Spearman correlation. Bars indicate SEM. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. NS, no significance.
versus 111.3 + 8.7, P = 0.003, unpaired twotailed t test; Fig. 7G ). We also assessed the role of anti-PDL1 therapy administered 4 days after intranasal bleomycin on murine pulmonary fibrosis. We noted significantly reduced weight loss in mice treated with anti-PDL1 compared to those treated with isotype antibody, as well as signifi cant reductions in pulmonary collagen content after administration of antibody against PDL1 compared to isotype before or after bleo mycin administration (Fig. 7H) . With the Sircol assay, pulmonary collagen content was higher in mice treated with the isotype control (156.2 ± 23.59) than that in mice treated with anti-PDL1 antibody (85.45 ± 14.63) (P = 0.03, unpaired twotailed t test; Fig. 7H ). Further more, significant differences in PD1 + CD4 + T cells and pSTAT3 (Y705) were also detected between isotype and anti-PDL1-treated cohorts (P < 0.0001 and P = 0.01, respectively, unpaired twotailed t test; Fig. 7, I and J). One mechanism by which PD1 reduces pSTAT3 expression is through decreased IL23R expression (fig. S13) . A sig nificant correlation between PD1 expression and pSTAT3 (Y705) was also noted in bleomycintreated mice (P = 0.0028; R 2 = 0.5398; Fig. 7K ). These findings provide in vivo confirmation of the rele vance of the PD1 pathway in interstitial lung disease.
DISCUSSION
These investigations identify PD1 upregulation as a critical media tor of human interstitial lung disease through increased IL17A production via the STAT3 signaling pathway. Key investigations have implicated aberrant STAT3 signaling and T H 17 cells in mu rine models of pulmonary fibrosis pathogenesis (9, 28, 29) . Here, we report that PD1 upregulation on human T H 17 cells creates not only an immunosuppressive microenvironment but also a profi brotic one. We demonstrate that IL17A and TGF1 produced by PD1 + CD4 + T cells induce collagen1 production from HLF, a pro cess that can be impeded by PD1 pathway blockade. Mechanisti cally, PD1 pathway blockade or smallmolecule inhibition of STAT3 results in reduced collagen production from HLF.
Immune dysfunction in CD4 + T cells secondary to PD1 up regulation in sarcoidosis subjects experiencing loss of pulmonary function has been noted (10) . However, the observation of a profi brotic component to PD1 upregulation has not been previously described; even more striking is the observation of PD1 regulation of IL17 and TGF expression. TGF expression by T regs has been reported (30) . We detected T H 17 cells that secrete intracellular and membrane bound TGF. T regs have plasticity, allowing them to differentiate into T H 17 cells in conditions of increased IL6/pSTAT3 expression (31) . We noted increased IL6 production from sarcoid osis CD4 + T cells of subjects experiencing disease progression; these same T cells exhibit PD1 upregulation. It is feasible that the TGF-secreting T H 17 cells began as T regs , but increased IL6 pro duction from sarcoidosis CD4 + T cells tilted the balance in favor of developing a T H 17 phenotype. We observed PD1 + T regs that also contain the transcription factor RORC in sarcoidosis and IPF sub jects. Strikingly, PD1 + and CD8 + T cell upregulation in liver and skin fibrosis has also been reported (34) .
The observation that PD1 can regulate STAT3 is particularly provocative. In cancers, such as melanoma and chronic lymphocytic leukemia (CLL), STAT3 regulation of PD1 on CD4 + and CD8 + T cells has been reported (35) . Reduced PD1 expression with STAT3 inhibition was noted on these cells, as well as reduced PDL1 ex pression on CLL cells, after treatment with the STAT3 inhibitor ibrutinib. It was also notable that ibrutinib only affected the PD1 pathway and not other checkpoint inhibitors (35) . We noted PD1 regulation of STAT3 in sarcoidosis CD4 + T cells. These observations in malignancies suggest that PD1 and STAT3 may directly or indi rectly regulate each other. In melanoma cells, STAT3 transcription has been shown to be negatively regulated by phosphatidylinositol 3kinase (PI3K) (36) . This pathway may have particular relevance to PD1 manipulation of STAT3 in sarcoidosis subjects due a recent report demonstrating the capacity of PD1 to inhibit PI3K expres sion in sarcoidosis CD4 + T cells (37) . It is possible that PD1 indi rectly regulates STAT3 transcription through inhibition of PI3K, resulting in increased STAT3. There is also a possible role for ex omes derived from T H 17 cells to regulate the PD1 pathway.
Administration of bleomycin to PD1 null mice resulted in sig nificant reductions in fibrosis. Despite the model's predilection to pulmonary fibrosis after bleomycin administration, we observed significant reductions in pulmonary fibrosis in the PD1 null mice compared to WT using multiple complementary assays. Adminis tration of antibody against PDL1 also demonstrated significant reductions in pulmonary collagen content. Mechanistically, direct targeting of the PD1 pathway demonstrated reductions in PD1 + CD4 + T cells, as well as pSTAT3 in these cells. Significant reductions in collagen production were noted by immunoblot analysis of the cell lysates, primarily by reductions in collagen1 and fibronectin expres sion. We did not observe distinctions in SMA between baseline and stimulated coculture conditions, most likely due to assessment at the 24hour time point. Previous reports have indicated a delay in the detection of myofibroblast differentiation at 24hour assess ments (38) . These data demonstrate the capacity of PD1 path way blockade to reduce pulmonary fibrosis due to acute lung injury (bleomycin).
This investigation is distinct from the previous publication re porting increased immunosuppressive PD1 + CD4 + T cells in sar coidosis subjects experiencing disease progression (10) . This work demonstrates that PD1 upregulation is also profibrotic through its capacity to enhance STAT3 expression, leading to production of profibrotic cytokines, such as TGF and IL17A. STATTIC inhibi tion of STAT3 has been shown to reduce collagen1 content and connective tissue growth factor using the bleomycin murine model of pulmonary fibrosis (39) (40) (41) . Furthermore, it has been previously demonstrated that genetic enhancement and ablation of STAT3 in the murine bleomycin model increase and reduce lung fibrosis, re spectively (42) .
A limitation of this study is that other immunologic and nonim munologic contributors to lung fibrosis were not examined. For example, mammalian sterile 20-like kinase 1 signaling from den dritic cells negatively regulates IL17-producing CD4 + T helper cell (T H 17) differentiation (43) . In addition, semaphorin 7A + T regs with reduced IL10 expression have also been implicated in IPF progres sion (44) . An investigation into the effects of PD1 on IL10 inhibi tion of IL17A production by CD4 + T cells is warranted to identify the aberrancies that facilitate progression of fibrotic lung disease in humans and murine models. In addition, whereas gene expression profiles of both IPF cohorts cluster around STAT1 and STAT4 ex pression, the T H 17 STAT3 bias is more apparent in the validation cohort. There are several factors that affect the distinctions in ex pression results between the two cohorts, including cell compart ment differences (PBMCs in discovery cohort versus whole blood in validation cohort), different RNA extraction methods (TRIzol in discovery cohort versus PAXgene in validation cohort), and differ ences in clinical practices across centers in two different continents (University of Chicago versus Imperial College London). STAT3 assessment in the discovery cohort revealed increased STAT3 ex pression among IPF patients with reduced TFS, thus validating the role of STAT3 in disease progression among IPF patients. Despite the reproducibility of the results, further validation using standard ized gene expression methods may be required in additional patient cohorts to confirm our findings.
In conclusion, these data identify relevant mechanisms for PD1 + CD4
+ T cell induction of pulmonary fibrosis. Blockade of the PD1 pathway significantly altered IL17A expression in CD4 + T cells via decreased pSTAT3 expression, resulting in significant declines in collagen1 production. In vivo investigations reveal significant de creases in bleomycin induced pulmonary fibrosis with the absence of PDCD1 in their genetic background or after administration of anti-PDL1 antibody. This work identifies readily available, U.S. Food and Drug Administration-approved therapeutics such as inhibitors of STAT3 signaling (for example, metformin and ibrutinib), which have been shown to alter epithelialmesenchymal transition (EMT) (45) , or antibodies directed against IL17A (46) as viable therapeu tic options for patients suffering from interstitial lung disease.
MATERIALS AND METHODS
Study design
This is a study using ex vivo human sample experiments and in vivo mouse experiments to demonstrate the ability of PD1 to induce pul monary fibrosis through STAT3 regulation of IL17A and TGF1 production. Primary data are located in table S2, and the details are described in Supplementary Materials and Methods. For study partic ipation, clinical and radiographic criteria were used to define sar coidosis as has been previously described (47, 48) . PBMCs of patients from the University of Cincinnati (UC), the Cleveland Clinic (CC), and the Vanderbilt University Medical Center (VUMC) were used. All subjects provided written informed consent that was approved by the appropriate institutional review boards (CC 14004, UC 20138269, and VUMC 040187). All investigations with human sub jects were conducted according to the principles expressed in the Helsinki Declaration. There were four subject cohorts: HC, subjects with sarcoidosis that have active disease, sarcoidosis subjects with resolved disease, and IPF patients. The sarcoidosis patients with ac tive disease were characterized by reductions in forced vital capacity (FVC), radiographic progression, or pulmonary symptom acceleration. Sarcoidosis subjects who had resolved disease were distinguished by normalized FVC or chest radiograph and resolution of pulmonary symptoms despite not being on immunosuppressive therapy. Pa tients with high PD1 expression were distinguished from patients with low PD1 according to percentage of positive cells and MFI. Subjects expressing low PD1 were defined as having PD1 percent ages and MFIs similar to HC. Study subject demographics are pro vided in Tables 1 and 2 .
Microarray data were analyzed on two previously published IPF patient cohorts evaluated at the University of Chicago (N = 45) (GSE27957) (13) and the Imperial College London (N = 55) (GSE93606) (49), using cluster 3 for hierarchical clustering (50) and the survival package of MedCalc software. Immunohistochemistry for PD1 and PDL1 was conducted as previously described (10) . Coculture ex periments were conducted as previously described (51) . Studies in volving large and independent experimental cohorts of mice were performed once. All bleomycin (52) and PD1 pathway blockade ex periments (53) were performed as previously described. Mouse co horts received antibody injections at the dosage regimens indicated in Supplementary Materials and Methods. Although the investigators were not blinded when they administered therapeutic antibodies, they were blinded while assessing the results. All murine procedures were performed according to the protocol approved by the Institutional Animal Care and Use Committee (protocol M170004300). Collagen quantification was conducted by hydroxyproline (54) or Sircol as say as previously described (55) . Primary data are located in table S2.
Statistical analysis
Comparisons between cohorts were performed using an unpaired twotailed Student's t test. Preblockade and PD1 pathway blockade cohort comparisons were analyzed using a paired Student's t test. Multiple group comparisons were performed using a oneway ANOVA with Tukey's post hoc test. Proliferation data were analyzed using the MannWhitney U test. Statistical analysis for all figures was carried out using Prism version 6.0 (GraphPad Software). A P < 0.05 was considered statistically significant. Fold change and false discovery rate values were calculated using the Significance Analysis of Mi croarrays (SAM) tools. All data were used in analysis.
SUPPLEMENTARY MATERIALS
www.sciencetranslationalmedicine.org/cgi/content/full/10/460/eaar8356/DC1 Materials and Methods Fig. S1 . PD-1 up-regulation in fibrotic lung disease. Fig. S11 . Reduced RORC expression after PD-1 blockade. Fig. S12 . IL-12 expression in IPF patients in the discovery cohort. Fig. S13 . Reduced IL-23R expression in PD-1 null bleomycin-treated mice. Table S1 . HLF and sarcoidosis PD-1 + CD4 + T cell coculture demonstrates increased collagen-1 synthesis. Table S2 . Primary data.
